Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. - Investor Relations & Filings

Listed IPO Jan 1999
Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,783 across all filing types
Latest filing 2026-04-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600201 · 1 venue

Key figures FY2024

Period ended 2024-12-31 · CNY
Headline annual figures for Jinyu Bio-Technology Co.,Ltd., fiscal year 2024, reported in CNY, with the source filing for each figure.
Total Revenues CNY 1.26B per the Annual Report filed 2025-04-24
Net Income CNY 104.15M per the Annual Report filed 2025-04-24
Total Assets CNY 6.76B per the Annual Report filed 2025-04-24
Total Equity CNY 5.42B per the Annual Report filed 2025-04-24
Cash from Ops CNY 289.55M per the Annual Report filed 2025-04-24

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司信息披露管理制度（2026年4月修订）
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" for a company, detailing the principles, procedures, responsibilities, and legal framework for information disclosure. It extensively references regulatory requirements, disclosure timing for annual, interim, and quarterly reports, and internal controls related to disclosure. It does not contain actual financial data, financial statements, or audit opinions, but rather outlines the company's policies and governance regarding information disclosure. This is a governance-related document describing internal rules and practices for disclosure compliance, not a financial report or announcement. Therefore, the document best fits the category of Governance Information (CGR).
2026-04-22 Chinese
生物股份关于子公司获准生产紧急免疫用口蹄疫疫苗的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (505 characters) regarding the approval for a subsidiary to produce an emergency vaccine. It includes a disclaimer about the accuracy of the announcement and mentions the company's plans and risks. There is no financial data, no detailed report, no meeting materials, no voting results, no management changes, no earnings information, or other detailed regulatory filings. The document is an official announcement about a specific operational update related to product approval. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial or governance content. Given the short length and nature of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous official announcements that do not fit other categories.
2026-04-07 Chinese
生物股份关于子公司取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about its subsidiary obtaining a new veterinary drug registration certificate. It details the product, regulatory approval, and impact on the company. The document is short (1098 characters) and serves as a formal notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval announcement. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-03-26 Chinese
生物股份关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business registration change, specifically the update of the company's business license and registered capital. It references a prior announcement about amendments to the company's articles of association but does not contain financial statements, management discussion, or detailed financial data. The document is short (697 characters) and serves as a formal notification of a corporate registration update rather than a financial report or detailed governance report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-06 Chinese
生物股份关于股东股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement regarding the release of pledged shares by a significant shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the shareholder's total holdings. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Major Shareholding Notification or related shareholder disclosures. Given the focus on share pledge release and shareholder holdings, the best fitting category is Major Shareholding Notification (MRQ). The document length is short and it is not a report or a certification, so it is not RNS or RPA. Therefore, the classification is MRQ with high confidence.
2026-02-03 Chinese
生物股份关于股东股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a major shareholder of the company. It details the number of shares pledged, the pledge dates, the shareholder's holding percentages, and assurances about the impact on company control and operations. There are no financial statements, earnings data, or management discussions. The document is a regulatory disclosure about share pledging, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on share pledge information, confirming it is not a full report or earnings release but a specific notification about shareholding changes.
2026-01-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.